SEC For	m 4 FORM 4	4 U		D STAT	ES S	SEC	URITIE	S AN	DE	XCHAN	NGE C	OMI	MISSI	ON					
							Washing	ton, D.C	C. 205	49					OME	3 APPRC	VAL		
to Section 16. Form 4 or Form 5 obligations may continue. See					IT OF CHANGES IN BENEFICIAL OWNERS pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5					
1. Name and Address of Reporting Person [*] Cheng Andrew						2. Issuer Name and Ticker or Trading Symbol <u>Akero Therapeutics, Inc.</u> [AKRO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) C/O AK	(Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/14/2023								X Officer (give title Other (specify below) below) President and CEO					
601 GATEWAY BOULEVARD, SUITE 350					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SOUTH SAN FRANCISCO CA 94080					X Form filed by One Reporting Person Form filed by More than One Reporting Person														
(City)	(Sta	ate) (a	Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - No	n-Deriva	tive S	Secu	rities Acq	uired,	Dis	posed of	, or Be	nefici	ally O	vned					
1. Title of Security (Instr. 3) Date (Month/Da					y/Year) if an		eemed ution Date, / th/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			nd See Bei Ow	mount of urities leficially ned Followin	For (D)	Ownership m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Tra	orted nsaction(s) tr. 3 and 4)			(Instr. 4)		
Common Stock 12/14/2								S ⁽¹⁾		1,628	D	\$20.	76	550,911		D			
		Та	ble II -				ies Acqu varrants,							ned					
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execut urity or Exercise (Month/Day/Year) if any		emed 4. Transau Code (I /Day/Year) 8)			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisal Expiration Date (Month/Day/Year		ite	Amount of		8. Price Derivati Security (Instr. 5	ve derivati Securiti	ve ies ially ng ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)			

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.

(A) (D)

Date Exercisable Expiration Date

> /s/ Jonathan Young, Attorney-12/18/2023

Amount or Number

of Shares

in-Fact

Title

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.